Cargando…
Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing
Developing new therapeutics for the treatment of childhood cancer has challenges not usually associated with adult malignancies. Firstly, childhood cancer is rare, with approximately 12,500 new diagnoses annually in the U.S. in children 18 years or younger. With current multimodality treatments, the...
Autores principales: | Ghilu, Samson, Kurmasheva, Raushan T., Houghton, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038510/ https://www.ncbi.nlm.nih.gov/pubmed/33916592 http://dx.doi.org/10.3390/jcm10071504 |
Ejemplares similares
-
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma
por: Ghilu, Samson, et al.
Publicado: (2022) -
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
por: Geier, Brian, et al.
Publicado: (2015) -
PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models
por: Yang, Juechen, et al.
Publicado: (2020) -
Genome-Edited Plants: Opportunities and Challenges for an Anticipatory Detection and Identification Framework
por: Ribarits, Alexandra, et al.
Publicado: (2021) -
New challenges of geriatric cardiology: from clinical to preclinical research
por: Malavolta, Marco, et al.
Publicado: (2017)